Advance articles
-
Accepted Manuscript
Rapid Communication 2 July 2024
Atypical melanocytes of an Atypical Spitz Tumor observed with Optical Super-High Magnification Dermoscopy
Maria Daviti and othersBritish Journal of Dermatology, ljae277, https://doi.org/10.1093/bjd/ljae277Published: 2 July 2024 Section: IMAGE CORRESPONDENCEA 64-year-old woman presented with a 6-mm pigmented lesion on her thigh. Dermatoscopy revealed the “starburst” dermatoscopic pattern of a spitzoid tumor. Before excision, the lesion was examined under × 400 magnification dermoscopy using the videoscope Fotofinder Medicam 1000 (Fotofinder System, Bad Birnbach, Germany) and in-vivo Reflectance Confocal Microscopy (RCM) (Vivascope 1500®, MAVIG GmbH, Munich, Germany).
-
Accepted Manuscript
Research Article 2 July 2024
Predictive features for effectiveness of dupilumab in elderly patients with atopic dermatitis: a real-world study
Qiqi Jia and othersBritish Journal of Dermatology, ljae278, https://doi.org/10.1093/bjd/ljae278Published: 2 July 2024 Section: Research letterIn this study we retrorespectively reviewed dupilumab's efficacy and safety profile in treating elderly patients with atopic dermatitis (AD) and explored the predictive indicators for its efficacy. After analysing data from 181 patients we found that dupilumab appears to be effective and well-tolerated in treating AD among elderly patients. More importantly, we found that disease severity and early response to dupilumab are associated with complete remission at week 24 and may be used as potential predictive indicators for dupilumab's efficacy.
-
Accepted Manuscript
Research Article 28 June 2024
A loss-of-function variant in KLF4 affecting zinc finger motifs causes progressive symmetric erythrokeratodermia
Zijuan Wang and othersBritish Journal of Dermatology, ljae275, https://doi.org/10.1093/bjd/ljae275Published: 28 June 2024 Section: Research letterWe identified a novel de novo variant (c.1234C>A, p.His412Asn) in KLF4, which is located within the first zinc finger motifs of KLF4, in a patient with progressive symmetric erythrokeratodermia. By dual-luciferase reporter assay, qRT-PCR, and immunofluorescence, we demonstrated that the KLF4 variant is a loss-of-function mutation, and the expression of SLURP1 and DSG1, both of which are transcriptionally regulated by KLF4, was downregulated.
-
Accepted Manuscript
Research Article 28 June 2024
“When you do not feel comfortable in your skin, you cannot get out of it” – A Qualitative Interview Study exploring Psychosocial Impact and Coping Strategies among Patients with Prurigo Nodularis
Louisa Schielein and othersBritish Journal of Dermatology, ljae274, https://doi.org/10.1093/bjd/ljae274Published: 28 June 2024 Section: Research letterPrurigo nodularis is a disease associated with severe chronic pruritus and therefore causes a substantial impact on quality of life. This study aims to explore the psychosocial burden of prurigo nodularis and the coping mechanisms employed by affected individuals to manage symptoms associated with the condition. Summarized, patients reported a profound impact on various aspects of their lives, including mental well-being, relationships, self-perception, leisure activities, occupation, sleep patterns, and clothing choices. Further, the disease led to social avoidance and isolation in patients.
-
Accepted Manuscript
Editorial 28 June 2024
Publications in the BJD: the impact of being read (and cited)
John A McGrathBritish Journal of Dermatology, ljae273, https://doi.org/10.1093/bjd/ljae273Published: 28 June 2024 Section: Editorial -
Accepted Manuscript
Article Commentary 27 June 2024
Network Pharmacology as a Platform for Drug Discovery for Hypertrophic Scars
Jennifer Y Wang and othersBritish Journal of Dermatology, ljae272, https://doi.org/10.1093/bjd/ljae272Published: 27 June 2024 Section: Commentary -
Accepted Manuscript
Research Article 27 June 2024
Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis
Kristina Hagenström and othersBritish Journal of Dermatology, ljae250, https://doi.org/10.1093/bjd/ljae250Published: 27 June 2024 Section: Original ArticleThis study investigated the utilization and potential negative effects of systemic glucocorticosteroids (SGCs) for atopic dermatitis (AD) in Germany. The prevalence of AD in 2020 was 4.07%, and 9.91% received a prescription for SGCs, significantly higher than those without AD (5.54%). Prescribing of SGC was higher in women, the elderly, and varied regionally. Over a three-year period, 51% received a SGC prescription in more than one quarter, and 15% in more than six quarters. Frequent prescription of SGC was associated with increased odds of developing osteoporosis and diabetes. The findings emphasize the considerable long-term prescriptions of SGC in persons with AD in Germany, with heightened odds of harmful side effects, indicating the need for improved healthcare practices.
-
Accepted Manuscript
Research Article 27 June 2024
Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder
Marion Wobse and othersBritish Journal of Dermatology, ljae256, https://doi.org/10.1093/bjd/ljae256Published: 27 June 2024 Section: Original ArticleCutaneous acral CD8+ T-cell lymphoproliferative disorder (TLPD) is a rare lymphoma entity with unknown pathogenesis. Deep sequencing and copy number analysis of CD8+ TLPD (n = 5) revealed homozygous deletions of the KIR3DL1 gene and loss of function mutation in the PIK3R1 as putative underlying oncogenic events.
-
Accepted Manuscript
Research Article 27 June 2024
Urticaria and the risk of cancer: a Danish population-based cohort study
Sissel B T Sørensen and othersBritish Journal of Dermatology, ljae264, https://doi.org/10.1093/bjd/ljae264Published: 27 June 2024 Section: Original ArticleSeveral case reports and studies have indicated that urticaria may be linked to occult cancers. We found that urticaria may be a marker of occult cancer but extensive diagnostic cancer screening in people with urticaria is unlikely to be cost-effective due to the low absolute risk.
-
Accepted Manuscript
Research Article 27 June 2024
Measurement properties and interpretability of the Patient-Reported Impact of Dermatological Diseases (PRIDD) measure
Rachael Pattinson and othersBritish Journal of Dermatology, ljae267, https://doi.org/10.1093/bjd/ljae267Published: 27 June 2024 Section: Original ArticleThe newly developed Patient-Reported Impact of Dermatological Diseases (PRIDD) measure has strong evidence of content validity, structural validity, internal consistency, acceptability, and feasibility. We aimed to test its remaining measurement properties - criterion validity, construct validity, test-retest reliability, measurement error and responsiveness - and establish the interpretability of scores against the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN). This study establishes PRIDD as a valid and reliable patient-reported measure with sufficient measurement properties, lack of floor and ceiling effects, and evidence-based score bandings to aid clinical interpretation.
-
Accepted Manuscript
Research Article 25 June 2024
COL10A1 expression distinguishes a subset of cancer-associated fibroblasts present in the stroma of high-risk basal cell carcinoma
Mauro Esposito and othersBritish Journal of Dermatology, ljae258, https://doi.org/10.1093/bjd/ljae258Published: 25 June 2024 Section: Original ArticleIn this study we aimed to characterize the stroma of the different Basal Cell Carcinoma (BCC) morphological subtypes (superficial, nodular, micronodular, sclerosing and basosquamous) with a focus on the low- vs high-risk stratification. We used laser capture microdissection to precisely define the stroma areas close to the tumor, followed by RNA sequencing. We identified COL10A1 as a marker of high-risk BCC, in particular of the sclerosing and basosquamous subtypes. Moreover, we demonstrated at the single cell level that COL10A1 is expressed by a specific CAF population present in the stroma of infiltrative BCC with extracellulatr matrix remodelling features. This opens up new tailored treatment options as well as a new prognostic biomarker for BCC progression.
-
Accepted Manuscript
Article Commentary 25 June 2024
Generalised pustular psoriasis, palmoplantar pustulosis, and plaque psoriasis have different survival rates and health care needs
Laura B von Kobyletzki and Åke SvenssonBritish Journal of Dermatology, ljae271, https://doi.org/10.1093/bjd/ljae271Published: 25 June 2024 Section: Commentary -
Accepted Manuscript
Rapid Communication 24 June 2024
A case of missing fingerprints
Mark Eisner and Neil RajanBritish Journal of Dermatology, ljae269, https://doi.org/10.1093/bjd/ljae269Published: 24 June 2024 Section: IMAGE CORRESPONDENCECongenital adermatoglyphia (a lack of fingerprints) is seen with variants in SMARCAD1 and can be associated with increased risk of cutaneous squamous cell carcinoma. Here we demonstrate adermatoglyphia in a patient with Huriez syndrome and compare with an unaffected volunteer.
-
Accepted Manuscript
Article Commentary 24 June 2024
The Safety of Topical versus Oral Steroids in Bullous Pemphigoid: Considerations for Retrospective Analyses
Kyle T Amber and Ron J FeldmanBritish Journal of Dermatology, ljae265, https://doi.org/10.1093/bjd/ljae265Published: 24 June 2024 Section: Commentary -
Accepted Manuscript
Research Article 24 June 2024
Life’s Essential 8, genetic susceptibility, and the risk of psoriatic disease: a prospective cohort study
Fujun Ouyang and othersBritish Journal of Dermatology, ljae268, https://doi.org/10.1093/bjd/ljae268Published: 24 June 2024 Section: Original ArticleThe study aimed to explore the association of Life's Essential 8 (LE8) score and genetic susceptibility with incident psoriatic disease (PsD). Our findings suggest that a higher LE8 score was associated with a lower risk of PsD in the entire population, regardless of genetic risk. Consequently, it should be recommended to matain high cardiovascular health status as a strategy for both preventing PsD and assessing associated risks.
-
Accepted Manuscript
Research Article 24 June 2024
Efficacy of hypnotherapy in chronic idiopathic pruritus: a single-arm prospective pilot study
Clemence Bertold and othersBritish Journal of Dermatology, ljae244, https://doi.org/10.1093/bjd/ljae244Published: 24 June 2024 Section: Research letterThere is a large unmet therapeutic need for chronic idiopathic pruritus. We show that hypnotherapy can relieve pruritus during several months.
-
Accepted Manuscript
Research Article 24 June 2024
High dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind, placebo-controlled study (ViDMe trial)
Julie De Smedt and othersBritish Journal of Dermatology, ljae257, https://doi.org/10.1093/bjd/ljae257Published: 24 June 2024 Section: Original ArticleObservational studies in cutaneous melanoma have indicated an inverse relationship between levels of 25-hydroxy vitamin D and Breslow thickness, as well as a protective effect of high 25- hydroxy vitamin D levels on clinical outcome. In this study we evaluate whether high dose vitamin D supplementation in curatively resected cutaneous melanoma reduces melanoma relapse.
-
Accepted Manuscript
Review Article 24 June 2024
Inflammasomes: emerging therapeutic targets in hidradenitis suppurativa?
Ciara Campbell and othersBritish Journal of Dermatology, ljae262, https://doi.org/10.1093/bjd/ljae262Published: 24 June 2024 Section: Review ArticleHidradenitis suppurativa is a debilitating skin condition with few effective treatments. Inflammasomes control the expression of key cytokines including IL-1beta which are partly responsible for HS pathogenesis. This review brings together the evidence supporting inflammasome dysregulation in HS and makes a case that inflammasomes make an attractive therapeutic target in the condition.
-
Accepted Manuscript
Research Article 20 June 2024
International study on prevalence of itch: examining the role of itch as a major global public health problem
Gil Yosipovitch and othersBritish Journal of Dermatology, ljae260, https://doi.org/10.1093/bjd/ljae260Published: 20 June 2024 Section: Original ArticleThe impact of demographic factors on pruritus/itch has rarely been assessed, with most studies limited to one region. We conducted an international study around the world to assess the effect of age, gender, ethnicity, and geographic regions on the prevalence of pruritus
-
Accepted Manuscript
Letter 18 June 2024
Comment on “Morphology: the mother of all biomarkers”
Francesca Prignano and Elia RosiBritish Journal of Dermatology, ljae237, https://doi.org/10.1093/bjd/ljae237Published: 18 June 2024 Section: Letter to the EditorComment on “Morphology: the mother of all biomarkers” by Miller et al.
-
Accepted Manuscript
Article Commentary 15 June 2024
The impact of vulval lichen sclerosus in young people: a call for better awareness, individualised maintenance plans and revised guidelines
Gayle FischerBritish Journal of Dermatology, ljae254, https://doi.org/10.1093/bjd/ljae254Published: 15 June 2024 Section: Commentary -
Accepted Manuscript
Article Commentary 15 June 2024
Spatial sequencing reveals transcriptional variation between amelanotic and pigmented acral melanoma
Martin McMahon and Dekker C DeaconBritish Journal of Dermatology, ljae253, https://doi.org/10.1093/bjd/ljae253Published: 15 June 2024 Section: Commentary -
Accepted Manuscript
Research Article 15 June 2024
Cytokeratin-17 expression is commonly observed in keratinocytic skin tumours and controls tissue homeostasis impacting HPV protein expression
Daniel Hasche and othersBritish Journal of Dermatology, ljae255, https://doi.org/10.1093/bjd/ljae255Published: 15 June 2024 Section: Original ArticleIn order to investigate whether papillomavirus oncoproteins affect keratin 17 (K17) expression, we analyzed K17 levels in skin tumor specimens of different animal models and humans. We could show that K17 is commonly expressed in skin tumors and that its presence is not directly linked to viral oncoprotein expression. Our data indicate that K17 expression is a common feature in skin tumorigenesis and that it is an important regulator of epithelial differentiation and thus may play a role in controlling viral maintenance.
-
Accepted Manuscript
Research Article 14 June 2024
Clinical characteristics associated with joint pain in hidradenitis suppurativa
Weiying Lu and othersBritish Journal of Dermatology, ljae251, https://doi.org/10.1093/bjd/ljae251Published: 14 June 2024 Section: Research letterAlthough patients with hidradenitis suppurativa (HS) report comorbid arthropathy, clinical characteristics associated with joint pain surrounding HS flares still remain obscure. We found that about 1 in 5 patients in our HS cohort endorsed peri-flare joint pain during their initial visit and that peri-flare joint pain was significantly associated with pain medication prescription (aOR 2.15, p=0.02) and diagnosis of inflammatory arthritis (aOR 4.14, p<0.001). Given the debilitating nature of HS flares, the addition of joint pain can further limit daily activities, underscoring the importance of a comprehensive approach to the management of HS patients.
-
Accepted Manuscript
Research Article 14 June 2024
Candidemia and Candida colonization in patients with epidermal necrolysis: a retrospective case series
Louise Chantelot and othersBritish Journal of Dermatology, ljae252, https://doi.org/10.1093/bjd/ljae252Published: 14 June 2024 Section: Research letterSepsis is a leading cause of death in patients with epidermal necrolysis (EN). Yet, fungal infections have rarely been reported. In a monocentric retrospective study conducted between 2000 and 2023 in the medical intensive care unit of the reference center for severe drug reactions in France, we report on the epidemiology of candidemia and Candida sp. colonization in patients with EN. 155 patients with EN were admitted to the ICU, of whom 36 had a positive Candida sp. skin culture without a candidemia, 12 developed a candidemia and 107 had a negative skin culture and no candidemia. Skin cultures showed a good sensitivity (89%; 95% CI (52%; 100%)) and excellent negative predictive values (99%; 95% CI (94%; 100%)) for candidemia.
-
Accepted Manuscript
Research Article 13 June 2024
Gene expression landscape of cutaneous squamous cell carcinoma progression
Tomas Bencomo and Carolyn S LeeBritish Journal of Dermatology, ljae249, https://doi.org/10.1093/bjd/ljae249Published: 13 June 2024 Section: Original ArticleWe re-analyzed RNA-Seq data of cutaneous squamous cell carcinoma (SCC) and its precursor lesions to define the transcriptome landscape at different stages of tumorigenesis while avoiding study-specific noise and improving statistical power. With this approach, we created a list of consensus genes altered in SCC development, characterized the cellular composition of SCC subtypes, defined the evolving landscape of gene fusions during SCC progression, and identified UV-responsive genes dysregulated in this malignancy. These findings provide a resource for researchers and propose new therapeutic targets for SCC.
-
Corrected Proof
Research Article 12 June 2024
Effectiveness of a nurse-led one-to-one education programme in addition to standard care in children with atopic dermatitis: a multicentre randomized control trial
Sebastien Barbarot and othersBritish Journal of Dermatology, ljae111, https://doi.org/10.1093/bjd/ljae111Published: 12 June 2024 Section: Original ArticleIn this academic randomized controlled trial, 176 patients were randomized in 11 centres. Our results did not show additional effectiveness in terms of long-term severity control between a 1-h nurse-led education intervention in children in addition to standard care, compared with standard care alone. However, it should be noted that the intervention reduced the fear of using topical steroids and may be beneficial for patients in the moderate AD subgroup.
-
Corrected Proof
Research Article 12 June 2024
Towards a roadmap for COSEB: the next steps in harmonization of outcomes for epidermolysis bullosa
Eva W H Korte and othersBritish Journal of Dermatology, ljae200, https://doi.org/10.1093/bjd/ljae200Published: 12 June 2024 Section: Research letterThe COSEB initiative aims for standardized and uniform measurement by developing core outcome sets for epidermolysis bullosa. This report describes the COSEB workshop organized in December 2023, which led to a broad stakeholder consensus-based roadmap. Moreover, it highlights novel features of COSEB, including the pro-active engagement of stakeholders from the very beginning and the appointment of a multi-stakeholder advisory panel.
-
Accepted Manuscript
Research Article 11 June 2024
EGFR/MEK inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege
David Rutkowski and othersBritish Journal of Dermatology, ljae243, https://doi.org/10.1093/bjd/ljae243Published: 11 June 2024 Section: Original ArticleThis study explores the impact of EGFR and MEK inhibitors on hair follicle immune privilege and inflammation, finding that these cancer treatments disrupt the protective immune environment of scalp hair follicles, leading to folliculitis. The research identifies a rise in specific immune cells and pro-inflammatory signals, suggesting that future treatment should focus on protecting hair follicle immunity and targeting specific inflammatory markers like IL33.
-
Accepted Manuscript
Research Article 11 June 2024
Epidemiology of Epidermolysis Bullosa in Chile
Francis Palisson and othersBritish Journal of Dermatology, ljae245, https://doi.org/10.1093/bjd/ljae245Published: 11 June 2024 Section: Research letterIn this manuscript we are presenting the first National Epidermolysis bullosa Epidemiology Study done in South America. Our manuscript describes not only population-level estimates, such as incidence, prevalence, and mortality of EB, but also genetic data which are unique to this under-represented population. We report new data about this rare disease showing comparable life expectancy to wealthier nations, demonstrating the value of specialized EB care centres.
-
Accepted Manuscript
Research Article 11 June 2024
Navigating the diagnostic journey of epidermolysis bullosa – a qualitative study on the lived experiences and needs of parents and patients
Eva W H Korte and othersBritish Journal of Dermatology, ljae242, https://doi.org/10.1093/bjd/ljae242Published: 11 June 2024 Section: Original ArticleThis qualitative study explored the lived experience and needs of parents of paediatric patients and adult patients with epidermolysis bullosa (EB), a group of rare genetic skin fragility disorders characterized by chronic blistering and wounding. Based on interviews with 26 participants, the authors developed ten themes highlighting the emotional impact of EB diagnosis, need for a timely and precise diagnosis, and importance of better disease understanding through clear and honest communication, while refraining from value-connoted disease terminology.
-
Accepted Manuscript
Research Article 11 June 2024
Social, Disease, and Diagnostic Factors Associated with Diagnostic Delays in Dermatomyositis: A Retrospective Cohort Study
Lindsey J Wanberg and othersBritish Journal of Dermatology, ljae247, https://doi.org/10.1093/bjd/ljae247Published: 11 June 2024 Section: Research letter -
Accepted Manuscript
Article Commentary 11 June 2024
Confetti Cure: Reversing the Genetic Kaleidoscope of Ichthyosis
Judith FischerBritish Journal of Dermatology, ljae248, https://doi.org/10.1093/bjd/ljae248Published: 11 June 2024 Section: Commentary -
Accepted Manuscript
Article Commentary 11 June 2024
Applying a Novel Optical Technique for Residual Cancer Detection with Accuracy Evaluation: A Cornerstone for Field Implementation
Byung Ho Oh and Ki Hean KimBritish Journal of Dermatology, ljae246, https://doi.org/10.1093/bjd/ljae246Published: 11 June 2024 Section: Commentary -
Accepted Manuscript
Research Article 8 June 2024
Comparison of incidence, causes and prognosis of adult and pediatric epidermal necrolysis: a population-based study in France
Thomas Bettuzzi and othersBritish Journal of Dermatology, ljae240, https://doi.org/10.1093/bjd/ljae240Published: 8 June 2024 Section: Original ArticleIn this study, childhood epidermal necrolysis was characterized by a lower incidence than adult epidermal necrolysis. Moreover, children were less likely to be administered a culprit drug before epidermal necrolysis onset, and presented a better prognosis than adults. These results suggest the existence of different underlying pathophysiological mechanisms between adults and children, and that the care of children with epidermal necrolysis should be properly adapted.
-
Accepted Manuscript
Research Article 8 June 2024
The emergence of circulating activated autoreactive Dsg3-specific Tfr cells is associated with long-term efficacy of RTX in PV patients
Vivien Hébert and othersBritish Journal of Dermatology, ljae220, https://doi.org/10.1093/bjd/ljae220Published: 8 June 2024 Section: Original ArticlePemphigus vulgaris is characterized by autoantibodies targeting keratinocytes adhesion proteins desmoglein Dsg1 and mainly Dsg3. Follicular T cells are essentil to drive B cells differenciation into Ab-producing plasma cells. Rituximab (anti-CD20 mAb) allows long-term remission even numerous years after treatment withdrawal. We found that its use is asscociated with the emergence of regulatory follicular autoreactive Dsg-specific T cells in patients with sustained complete remission.
-
Accepted Manuscript
Review Article 7 June 2024
Recent Advances in Understanding the Molecular Basis of Infantile Haemangioma Development
Raka Mitra and othersBritish Journal of Dermatology, ljae241, https://doi.org/10.1093/bjd/ljae241Published: 7 June 2024 Section: Review ArticleThis review investigates the molecular mechanisms behind the progression and phases of Infantile Haemangioma with identification of key signalling pathways and targeted proteins. Such knowledge will offer valuable insights for both researchers and clinicians in this field, and deeper comprehension of tissue remodelling and angiogenesis.
-
Accepted Manuscript
Review Article 5 June 2024
The role of OX40L/OX40 axis signalling in atopic dermatitis
Emma Guttman-Yassky and othersBritish Journal of Dermatology, ljae230, https://doi.org/10.1093/bjd/ljae230Published: 5 June 2024 Section: Review Article -
Accepted Manuscript
Research Article 5 June 2024
Genomic profiling of a skin adnexal carcinomas cohort using a comprehensive high throughput sequencing approach
Baptiste Louveau and othersBritish Journal of Dermatology, ljae233, https://doi.org/10.1093/bjd/ljae233Published: 5 June 2024 Section: Research letterIn this study, we have conducted a comprehensive molecular characterization of a cohort of 77 SAC and compared our findings to those of other skin carcinomas.
We highlighted genomic profiles bringing insights regarding classification, tumorigenesis processes and therapeutic options.
-
Accepted Manuscript
Article Commentary 5 June 2024
Basal cell carcinoma incidence trends - can we stop the surge?
Zoe C Venables and Marlies WakkeeBritish Journal of Dermatology, ljae239, https://doi.org/10.1093/bjd/ljae239Published: 5 June 2024 Section: Commentary -
Accepted Manuscript
Research Article 4 June 2024
Prevalence, Incidence and Treatment Patterns of Prurigo Nodularis in England: A Retrospective Database Analysis
Donia Bahloul and othersBritish Journal of Dermatology, ljae207, https://doi.org/10.1093/bjd/ljae207Published: 4 June 2024 Section: Original ArticleThe epidemiology of PN was consistent with other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs, as compared with milder patients.
-
Accepted Manuscript
Research Article 4 June 2024
Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial
Taku Fujimura and othersBritish Journal of Dermatology, ljae231, https://doi.org/10.1093/bjd/ljae231Published: 4 June 2024 Section: Original ArticleThis study describes results from a phase II trial of nivolumab in combination with the PAI-1 inhibitor TM5614 in patients with melanoma whose disease had progressed on anti-PD-1 Abs monotherapy. The overall response rate of this combination therapy was 25.9% in 27 patients who was refractory to anti-PD-1 Abs monotherapy in the protocol per set cohort. The safety profile of the combination was favorable. TM5614 in combination with nivolumab is well-tolerated and effective for anti-PD-1 Abs-refractory, unresectable melanoma. Further evaluation of OS and PFS for anti-PD-1 Ab-refractory, unresectable melanoma cohorts should be performed in a pivotal phase III trial in the future.
-
Accepted Manuscript
Research Article 3 June 2024
Mosaic EGFR exon 20 in-frame insertion pathogenic variants are associated with papular epidermal nevus with “skyline” basal cell layer (PENS)
Didier Bessis and othersBritish Journal of Dermatology, ljae236, https://doi.org/10.1093/bjd/ljae236Published: 3 June 2024 Section: Research letterPapular epidermal nevus with “skyline” basal cell layer (PENS) is a type of keratinocytic epidermal nevus for which the molecular genetic mechanism has not yet been identified. EGFR ex20ins could represent a new and specific genetic somatic marker of PENS
-
Corrected Proof
Research Article 31 May 2024
Granuloma annulare and the risk of autoimmune conditions: a multicentre retrospective cohort analysis
David Garate and othersBritish Journal of Dermatology, ljae218, https://doi.org/10.1093/bjd/ljae218Published: 31 May 2024 Section: Research letterPrior studies and case reports have postulated potential associations between granuloma annulare (GA) and various autoimmune conditions, but these relationships remain unclear. Using the TriNetX Research Network, we found that GA was significantly associated with an increased risk of systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroiditis and type 1 diabetes mellitus, along with point estimates suggesting an increased risk of systemic sclerosis and uveitis. Overall, our study uses epidemiological data to provide valuable evidence supporting an increased risk of autoimmune disorders in people with GA.
-
Corrected Proof
Research Article 31 May 2024
The impact of irritant challenge on the skin barrier and myeloid-resident immune cells in women who are postmenopausal is modulated by hormone replacement therapy
Orsolya Kiss and othersBritish Journal of Dermatology, ljae226, https://doi.org/10.1093/bjd/ljae226Published: 31 May 2024 Section: Original ArticleSex hormone changes during menopausal transition contribute to declining skin health. However, how menopause and its treatment by hormone replacement therapy (HRT) impact the skin barrier and immune system is unclear. This study contributes by demonstrating that HRT postmenopause has minimal impact on skin structure or skin-resident immune cells under normal conditions but may enhance the physical epidermal barrier and promote the accumulation of inflammatory macrophages and dendritic cells in the dermis under proinflammatory conditions.
-
Accepted Manuscript
Research Article 31 May 2024
Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa
Alessia Primerano and othersBritish Journal of Dermatology, ljae225, https://doi.org/10.1093/bjd/ljae225Published: 31 May 2024 Section: Original ArticleProgressive fibrosis is a consequence of lack of type VII collagen in recessive dystrophic epidermolysis bullosa (RDEB) and it causes the development of disabling secondary disease manifestations. Histone acetylation is decreased in RDEB skin and fibroblasts likely due to histone deacetylase (HDAC) hyperactivation. HDAC inhibitor administration reduces transforming growth factor-β levels and fibroblast activation mitigating fibrosis progression and the development of disabling disease complications.
-
Accepted Manuscript
Research Article 31 May 2024
Mapping oSCORAD and SCORAD to EASI to facilitate large-scale meta-analyses of molecular data
Matthias Hübenthal and othersBritish Journal of Dermatology, ljae232, https://doi.org/10.1093/bjd/ljae232Published: 31 May 2024 Section: Research letterWe used data from 1501 patients to build mathematical models for mapping between common measures of AD severity, including oSCORAD, SCORAD and EASI. Therewith, we facilitate progress in harmonizing patient data across studies, enabling important comparative analyses at scale.
-
Accepted Manuscript
Research Article 31 May 2024
Using network pharmacology to discover potential drugs for hypertrophic scars
Yi Zhang and othersBritish Journal of Dermatology, ljae234, https://doi.org/10.1093/bjd/ljae234Published: 31 May 2024 Section: Original Article -
Accepted Manuscript
Review Article 31 May 2024
The Dermatology Life Quality Index (DLQI) as the Primary Outcome in Randomised Clinical Trials: A systematic review
Jeffrey R Johns and othersBritish Journal of Dermatology, ljae228, https://doi.org/10.1093/bjd/ljae228Published: 31 May 2024 Section: Systematic reviewIn dermatology, QoL measures in clinical trials have mostly been used as secondary outcome measures, despite validation of Quality of Life (QoL) measures often being more extensive than for other disease severity measures. Patient reported outcomes are now being considered as primary measures for phase III trials to evaluate the intervention effectiveness, to support registration of clinical trials, product approvals, and labelling claims. This study reports on24 peer reviewed journal articles that used the Dermatology Life Quality Index (DLQI) as primary outcome, derived from a systematic review of randomised controlled trials (RCTs), utlising DLQI and covering all diseases and interventions. Researchers and clinicians can use this data to inform decisions for further use of the DLQI.
-
Accepted Manuscript
Research Article 30 May 2024
Spatial transcriptome analysis of amelanotic acral melanoma reveals distant molecular determinants compared to pigmented acral melanoma
Myoung Eun Choi and othersBritish Journal of Dermatology, ljae224, https://doi.org/10.1093/bjd/ljae224Published: 30 May 2024 Section: Original ArticleSpatial transcriptome analysis revealed significant enrichment of dysregulated translation pathways and chaperone/ubiquitin genes but significantly decreased interferon signalling pathways, antigen presentation and processing pathways, and melanin biosynthesis pathways in amelanotic acral melanomas compared to pigmented acral melanomas. Moreover, the number of monocytes and endothelial cells increased, whereas that of CD8 T cells and M1 macrophages significantly decreased in amelanotic acral melanoma compared with pigmented acral melanoma.
-
Accepted Manuscript
Research Article 29 May 2024
Sodium-glucose cotransporter protein-2 inhibitors for diabetes and the reduced risk of inflammatory skin diseases
Chin-Hsuan Shen and othersBritish Journal of Dermatology, ljae229, https://doi.org/10.1093/bjd/ljae229Published: 29 May 2024 Section: Research letterTreatment with SGLT2i was associated with a decreased risk of new-onset inflammatory skin diseases including vitiligo, acne vulgaris, rosacea, and urticaria in diabetic patients. Prospective studies and clinical trials are warranted to validate the safety and efficacy of SGLT2i in patients with diabetes and concomitant inflammatory skin diseases.
-
Accepted Manuscript
Research Article 28 May 2024
Responsiveness of the condition-specific OVAMA questionnaire to measure symptoms and appearance in patients with vascular malformations
Merel L E Stor and othersBritish Journal of Dermatology, ljae213, https://doi.org/10.1093/bjd/ljae213Published: 28 May 2024 Section: Original ArticlePreviously, the OVAMA (Outcome Measures for VAscular Malformations) questionnaire was developed to uniformly measure symptoms and appearance, i.e., condition-specific core outcome domains, in patients with vascular malformations. This study was performed to evaluate the responsiveness of the OVAMA questionnaire following the criterion approach of testing predefined hypotheses about expected relationships between the OVAMA questionnaire and other outcome measurement instruments and showed that the OVAMA questionnaire is responsive to changes in symptoms and appearance in patients with vascular malformations. The OVAMA questionnaire can now be used to evaluate the effect of treatment from the patient’s perspective and to achieve uniformity in outcome reporting.
-
Corrected Proof
Research Article 27 May 2024
Risk of death, major adverse cardiac events and relapse in patients with bullous pemphigoid treated with systemic or topical corticosteroids
Khalaf Kridin and othersBritish Journal of Dermatology, ljae219, https://doi.org/10.1093/bjd/ljae219Published: 27 May 2024 Section: Original ArticleOur study compared systemic and topical corticosteroid treatments in patients with bullous pemphigoid. Utilizing a retrospective cohort study within the TriNetX US Collaborative Network, we found that systemic corticosteroid use increased the risk of death (HR 1.4, 95% CI 1.3–1.6; P < 0.001), major cardiovascular events and infections, while decreasing the risk of relapse (HR 0.9, 95% CI 0.8–0.9; P = 0.002) vs. topical treatment. Despite the relapse risk, topical corticosteroid treatment may be advantageous owing to its significantly lower mortality risk.
-
Corrected Proof
Discussion 27 May 2024
Living in my own skin: dermatological concerns and gender-affirming care as a trans person with neurofibromatosis type 1
Alex Barbieri and othersBritish Journal of Dermatology, ljae170, https://doi.org/10.1093/bjd/ljae170Published: 27 May 2024 Section: PerspectivesWe provide patient and clinician perspectives on the dermatological outcomes of patients with neurofibromatosis type 1 (NF1) seeking gender-affirming hormone therapy. This perspectives article speaks to the psychosocial challenges that patients with NF1 may face due to the visible signs and symptoms of their disease. The theoretical role that hormones may play in the development of cutaneous neurofibromas is also addressed.
-
Corrected Proof
Editorial 23 May 2024
Paper mill-backed writers: Here, there and everywhere?
John A McGrath and Shehnaz AhmedBritish Journal of Dermatology, ljae227, https://doi.org/10.1093/bjd/ljae227Published: 23 May 2024 Section: Editorial -
Accepted Manuscript
Article Commentary 23 May 2024
Expanding the knowledge about the TNF-α induced GSDME-mediated pyroptosis in psoriasis
Helen VaherBritish Journal of Dermatology, ljae223, https://doi.org/10.1093/bjd/ljae223Published: 23 May 2024 Section: Commentary -
Corrected Proof
Research Article 23 May 2024
Hidradenitis suppurativa, systemic inflammatory response syndrome and sepsis: a database study
Edigin Ehizogie and othersBritish Journal of Dermatology, ljae221, https://doi.org/10.1093/bjd/ljae221Published: 23 May 2024 Section: Research letterHidradenitis suppurativa (HS) has unclear pathophysiology and aetiology, but it is not an infectious disease. However, HS is frequently mistaken for an infection and patients with HS are treated for recurrent bacterial abscesses or admitted for sepsis. A systematic literature search that is published as a separate paper did not identify an index case that demonstrates that sepsis can originate in an HS lesion. However, because patients with HS get admitted for sepsis anyway, we wanted to characterize them.
-
Corrected Proof
Research Article 22 May 2024
Prevalence, incidence, mortality and healthcare resource use for generalized pustular psoriasis, palmoplantar pustulosis and plaque psoriasis in England: a population-based cohort study
Monika Frysz and othersBritish Journal of Dermatology, ljae217, https://doi.org/10.1093/bjd/ljae217Published: 22 May 2024 Section: Original ArticleGeneralized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP) are chronic inflammatory skin conditions and have different characteristics than plaque psoriasis. Using the Clinical Practice Research Datalink, this study provides further evidence that GPP and PPP are distinct diseases from plaque psoriasis. In addition, in England, patients with GPP were found to have higher healthcare resource utilization and lower survival than patients with plaque psoriasis.
-
Corrected Proof
Research Article 22 May 2024
Single-cell transcriptomic analysis identifies infiltrating plasmacytoid dendritic cells in psoriasis epidermis
Longlong Luo and othersBritish Journal of Dermatology, ljae210, https://doi.org/10.1093/bjd/ljae210Published: 22 May 2024 Section: Research letterOur study unveils the cellular and molecular dynamics in psoriasis epidermis, revealing diverse cell states and their interactions driving inflammation and altered developmental trajectories. Importantly, a previously overlooked plasmacytoid dendritic cell cluster with inflammatory properties was identified in the epidermis of chronic psoriasis lesions, suggesting a potential role for these cells in chronic psoriasis.
-
Corrected Proof
Correction 22 May 2024
Correction to: Loss-of-function variants in GLMN are associated with generalized skin hyperpigmentation with or without glomuvenous malformation
British Journal of Dermatology, ljae212, https://doi.org/10.1093/bjd/ljae212Published: 22 May 2024 Section: Correction -
Corrected Proof
Editorial 22 May 2024
Tuning up the chords of consensus research with the ACcurate COnsensus Reporting Document (ACCORD)
Esther J van ZuurenBritish Journal of Dermatology, ljae215, https://doi.org/10.1093/bjd/ljae215Published: 22 May 2024 Section: Editorial -
Corrected Proof
Research Article 21 May 2024
Growing up with juvenile vulvar lichen sclerosus: the experiences and care needs of adult women with lichen sclerosus since childhood – a qualitative exploration
Beth Morrel and othersBritish Journal of Dermatology, ljae203, https://doi.org/10.1093/bjd/ljae203Published: 21 May 2024 Section: Original ArticleThrough a qualitative study, it is shown that age-appropriate, life phase-adjusted, individually tailored care for women diagnosed with vulvar lichen sclerosus (VLS) in childhood or adolescence is needed. Care and guidance from childhood onward should encompass a standard of care, taking interpersonal differences into account, including differences in support network and coping strategies, adapted to the individual as her needs change over time. In addition, the findings demonstrate the need to improve awareness and knowledge about juvenile and adult VLS among healthcare providers, especially primary care providers, and among the general public.
-
Corrected Proof
Research Article 21 May 2024
Mutational landscape and tumour mutational burden in adults with malignant melanoma arising from congenital naevi
Grace B Hanrahan and Hillary C TsibrisBritish Journal of Dermatology, ljae214, https://doi.org/10.1093/bjd/ljae214Published: 21 May 2024 Section: Research letterWe evaluated the genetic mutations, tumour mutational burden (TMB) and ultraviolet (UV) signature pattern in melanomas arising in congenital melanocytic naevi (CMN) in adults treated at the Dana–Farber Cancer Institute. Whereas paediatric CMN melanomas are characterized by NRAS mutations and reportedly lack BRAF and PTEN mutations, analysis showed that adult CMN melanomas contain BRAF, PTEN and TERT promotor mutations. Adult CMN melanomas showed low average TMB and an absent UV signature, suggesting lower UV damage in adult CMN melanoma than in other subtypes. Patients treated with immune checkpoint inhibition showed refractory disease progression, potentially attributable to low TMB. Findings suggest adult CMN melanoma may have distinct genetic properties from paediatric CMN melanoma and show immunotherapy resistance.
-
Corrected Proof
Research Article 21 May 2024
Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life
Daniel Lyons and othersBritish Journal of Dermatology, ljae216, https://doi.org/10.1093/bjd/ljae216Published: 21 May 2024 Section: Research letterHidradenitis suppurativa (HS) has a significant impact on patients’ quality of life (QoL) and mortality. We report the use of semaglutide and its impact on disease control and QoL in 30 patients with obesity attending an HS specialty clinic. These retrospective data suggest that the addition of semaglutide to standard HS treatments results in improvement in QoL and fewer HS flares. The retrospective nature of the study is a limitation. Placebo-controlled randomized clinical trials should be done in HS to assess the efficacy of semaglutide in this debilitating condition.
-
Corrected Proof
Correction 20 May 2024
Correction to: Breastfeeding decreases the risk of developing psoriasis through to early adulthood
British Journal of Dermatology, ljae208, https://doi.org/10.1093/bjd/ljae208Published: 20 May 2024 Section: Correction -
Corrected Proof
Research Article 17 May 2024
Increased risk of depression and anxiety in individuals with Darier disease
Philip Curman and othersBritish Journal of Dermatology, ljae195, https://doi.org/10.1093/bjd/ljae195Published: 17 May 2024 Section: Research letterPatients with Darier disease have an increased risk of depression and anxiety, which agrees with patterns of increased prescription of antidepressants and anxiolytics in people with the disease.
-
Accepted Manuscript
Research Article 16 May 2024
Downregulation of Ebp1Khib210 promotes keratinocyte proliferation through induction of TIF-IA-mediated rRNA synthesis
Junqin Li and othersBritish Journal of Dermatology, ljae194, https://doi.org/10.1093/bjd/ljae194Published: 16 May 2024 Section: Original ArticleAlthough dysregulation of Khib modification has been reported in psoriasis, the possible pathogenic role of Khib modification in psoriasis has not been elucidated. The keratinocyte proliferation enhanced through induction of TIF-IA-mediated rRNA synthesis in EBP1K210A cells. The Khib of EBP1 at K210 play a potential role in the pathogenesis of psoriasis.
-
Corrected Proof
Research Article 16 May 2024
Fibroblasts with high matrix metalloproteinase 2 expression regulate CD8+ T-cell residency and inflammation via CD100 in psoriasis
Canbin Dong and othersBritish Journal of Dermatology, ljae205, https://doi.org/10.1093/bjd/ljae205Published: 16 May 2024 Section: Original ArticleFibroblasts, by modulating matrix metalloproteinase (MMP)2 and MMP9, induce CD100 shedding from CD8+ T cells, generating soluble CD100 (sCD100), which promotes inflammatory mediator production via PLXNB2, intensifying the inflammation in psoriasis. sCD100 further stimulates fibroblasts to produce MMP2, creating a feedback loop that exacerbates inflammation. Additionally, fibroblasts enhance CD103 expression on CD8+ T cells, influencing psoriasis relapse dynamics by promoting T-cell residency.
-
Corrected Proof
Research Article 16 May 2024
The sunbed trend in Ireland
Amy Long and othersBritish Journal of Dermatology, ljae209, https://doi.org/10.1093/bjd/ljae209Published: 16 May 2024 Section: Research letterThis research letter provides a report on commercial sunbed prevalence in Ireland since the introduction of the Public Health (Sunbeds) Act 2014, and a review of current legislation on indoor tanning in Ireland and the UK.
-
Corrected Proof
Research Article 16 May 2024
Increased incidence of co-trimoxazole-induced rash in patients on systemic corticosteroid treatment for toxicity associated with immune checkpoint inhibitors
Daniel Yiu and othersBritish Journal of Dermatology, ljae202, https://doi.org/10.1093/bjd/ljae202Published: 16 May 2024 Section: Research letterOur cross-sectional study demonstrates that there is a high rate of co-trimoxazole-induced drug rash in patients treated for immune-related adverse events, with those developing rash appearing to have a reduced survival.
-
Corrected Proof
Article Commentary 16 May 2024
Ecological evidence for melanoma overdiagnosis in Denmark
Catherine M OlsenBritish Journal of Dermatology, ljae206, https://doi.org/10.1093/bjd/ljae206Published: 16 May 2024 Section: Commentary -
Corrected Proof
Article Commentary 16 May 2024
Paediatric lymphomatoid papulosis: a benign clonal T-cell disorder that is a harbinger of haematological malignancy
Maxime BattistellaBritish Journal of Dermatology, ljae211, https://doi.org/10.1093/bjd/ljae211Published: 16 May 2024 Section: Commentary -
Corrected Proof
Research Article 15 May 2024
Incidence and trends of first basal cell carcinomas in France between 1980 and 2019: a regional population-based registry study
Karima Hammas and othersBritish Journal of Dermatology, ljae201, https://doi.org/10.1093/bjd/ljae201Published: 15 May 2024 Section: Original ArticleThis population-based study examined 48 989 cases of first basal cell carcinoma (BCC) diagnoses in two French districts between 1980 and 2019. The median age at diagnosis was 69 years, with BCCs predominantly located on the head and neck (68.8%). BCC incidence rates increased substantially over time, from 59.9 to 183.1 per 100 000 person-years in Doubs between 1980 and 2016, and from 139.2 to 182.8 in Haut-Rhin from 1991 to 2019; men showed higher rates after 60 years, while women had higher rates in the 40–49 years age group. The study suggests a slowing in the incidence increase post-2000, possibly reflecting preventive measures, pointing to the present need for effective prevention strategies, given the continual rise in BCC incidence in France.
-
Corrected Proof
Research Article 13 May 2024
Secukinumab in adult patients with lichen planus: efficacy and safety results from the randomized placebo-controlled proof-of-concept PRELUDE study
Thierry Passeron and othersBritish Journal of Dermatology, ljae181, https://doi.org/10.1093/bjd/ljae181Published: 13 May 2024 Section: Original ArticleWe present results from a basket-designed, double-blind, placebo-controlled, parallel-group, phase II proof-of-concept study that evaluated the efficacy and safety of secukinumab 300 mg over 32 weeks in adult patients with biopsy-proven cutaneous lichen planus, mucosal lichen planus or lichen planopilaris that was inadequately controlled by standard therapies.
-
Corrected Proof
Research Article 13 May 2024
Diagnostic accuracy of autofluorescence-Raman microspectroscopy for surgical margin assessment during Mohs micrographic surgery of basal cell carcinoma
Radu A Boitor and othersBritish Journal of Dermatology, ljae196, https://doi.org/10.1093/bjd/ljae196Published: 13 May 2024 Section: Original ArticleAutofluorescence (AF)–Raman microspectroscopy has been shown to identify residual basal cell carcinoma on both frozen and fresh skin specimens immediately after excision by Mohs micrographic surgery. This first diagnostic test of accuracy of AF–Raman microspectroscopy on full-face Mohs tissue layers from 130 patients shows that, with improvements in tissue processing, the AF–Raman instrument is a viable technique for intraoperative assessment of surgical margins.
-
Corrected Proof
Research Article 13 May 2024
‘Feeling like a second-class citizen’: exploring the impact, self-management and existing support for adults living with acne and/or post-inflammatory hyperpigmentation and scarring
Carys Dale and othersBritish Journal of Dermatology, ljae190, https://doi.org/10.1093/bjd/ljae190Published: 13 May 2024 Section: Research letterThis article investigates how living with, and self-managing, acne and post-inflammatory hyperpigmentation and scarring impacts adults living with these conditions. Eight adults took part in individual qualitative interviews. Framework analysis generated four themes: (1) acne blame; (2) control at any cost; (3) the business of skinfluencers; and (4) ‘it’s your hormones’. Those with acne and PIH&S are currently underserved by dermatology and psychodermatology provision, and additional funding and research is needed to provide psychological and self-management support for this group.
-
Corrected Proof
Research Article 13 May 2024
Mutational profiling of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder does not resemble nodal peripheral T-cell lymphomas with a follicular helper T-cell phenotype
Marta Rodríguez and othersBritish Journal of Dermatology, ljae192, https://doi.org/10.1093/bjd/ljae192Published: 13 May 2024 Section: Research letterWe performed targeted next-generation sequencing of 62 genes, previously described as being mutated in T-cell lymphomas, in 15 formalin-fixed paraffin-embedded samples from patients with primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder.
-
Corrected Proof
Research Article 13 May 2024
Treating epidermolytic ichthyosis and ichthyosis with confetti with epidermal autografts cultured from revertant skin
Kana Tanahashi and othersBritish Journal of Dermatology, ljae193, https://doi.org/10.1093/bjd/ljae193Published: 13 May 2024 Section: Original ArticleWe successfully produced cultured epidermal autografts from the genetically confirmed revertant skin of two patients with mosaic epidermolytic ichthyosis and one patient with ichthyosis with confetti, and confirmed by amplicon sequencing and droplet digital PCR analysis that cultured epidermal autografts mainly consist of revertant wild-type cells. Single-cell RNA sequencing analysis confirmed the normal proliferation and safety profile of cultured epidermal autografts. Cultured epidermal autografts from normal skin have the potential to be a safe and local treatment option for severe epidermolytic ichthyosis and ichthyosis with confetti.
-
Corrected Proof
Article Commentary 13 May 2024
Vitamin D status in patients with erythropoietic protoporphyria taking the systemic photoprotective agent afamelanotide
Lesley E RhodesBritish Journal of Dermatology, ljae191, https://doi.org/10.1093/bjd/ljae191Published: 13 May 2024 Section: Commentary -
Corrected Proof
Article Commentary 13 May 2024
Bursting the bubble on diagnostics: artificial intelligence in autoimmune bullous disease
Brent J Doolan and Bjorn R ThomasBritish Journal of Dermatology, ljae197, https://doi.org/10.1093/bjd/ljae197Published: 13 May 2024 Section: Commentary -
Corrected Proof
Article Commentary 13 May 2024
MiTES: itch or pain?
Cristina HasBritish Journal of Dermatology, ljae198, https://doi.org/10.1093/bjd/ljae198Published: 13 May 2024 Section: Commentary -
Corrected Proof
Article Commentary 13 May 2024
Insulin resistance and psoriasis
Shirley P Parraga and Steven R FeldmanBritish Journal of Dermatology, ljae199, https://doi.org/10.1093/bjd/ljae199Published: 13 May 2024 Section: Commentary -
Corrected Proof
Research Article 12 May 2024
Impact of pruritus on patient fatigue: a cross-sectional study
Luis F Andrade and othersBritish Journal of Dermatology, ljae173, https://doi.org/10.1093/bjd/ljae173Published: 12 May 2024 Section: Research letterThrough an analysis of 114 015 adult patients in the NIH All of Us research programme – an initiative structured to incorporate populations that have been historically under-represented in biomedical research – we concluded that diagnoses of chronic pruritus and pruritus-related conditions were significantly associated with increased fatigue compared with age-, sex- and race/ethnicity propensity-matched controls without pruritus.
-
Corrected Proof
Discussion 10 May 2024
Redefine ‘benign’: a misnomer in the context of patients with genetic skin tumour syndromes
Julie Robinson and othersBritish Journal of Dermatology, ljae185, https://doi.org/10.1093/bjd/ljae185Published: 10 May 2024 Section: Perspectives -
Corrected Proof
Article Commentary 8 May 2024
Interleukin-17 blockade by secukinumab was not effective in controlling lichen planus in a randomized controlled clinical trial
Claudia GüntherBritish Journal of Dermatology, ljae186, https://doi.org/10.1093/bjd/ljae186Published: 8 May 2024 Section: Commentary -
Corrected Proof
Article Commentary 4 May 2024
The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a’s role in treating mycosis fungoides/Sézary syndrome
Rudolf StadlerBritish Journal of Dermatology, ljae188, https://doi.org/10.1093/bjd/ljae188Published: 4 May 2024 Section: Commentary -
Corrected Proof
Article Commentary 4 May 2024
Nemolizumab: a new key player in the treatment of prurigo nodularis
Adam ReichBritish Journal of Dermatology, ljae189, https://doi.org/10.1093/bjd/ljae189Published: 4 May 2024 Section: Commentary -
Corrected Proof
Rapid Communication 4 May 2024
Deceptive pigment changes in neoadjuvant sonidegib therapy for basal cell carcinoma
Shenxi Zhang and Menglong RanBritish Journal of Dermatology, ljae187, https://doi.org/10.1093/bjd/ljae187Published: 4 May 2024 Section: IMAGE CORRESPONDENCE -
Corrected Proof
Research Article 2 May 2024
Prevalence of ichthyoses in Denmark: a nationwide registry-based study
David Thein and othersBritish Journal of Dermatology, ljae177, https://doi.org/10.1093/bjd/ljae177Published: 2 May 2024 Section: Research letterThe results demonstrate a prevalence of 1.6 per 10 000 for all types of ichthyoses, based on large Danish national patient registries, including all patients with relevant diagnoses alive on 31 December 2021. A study of this size and depth has not been completed before but may still underestimate the prevalence and potential burden of the diseases.
-
Corrected Proof
Research Article 30 April 2024
Concomitant moderate-to-severe cutaneous lesions have marked impact on quality of life in patients with active systemic lupus erythematosus: a cross-sectional insight from two phase III randomized clinical trials in adults
Mischa J Mallbris and othersBritish Journal of Dermatology, ljae183, https://doi.org/10.1093/bjd/ljae183Published: 30 April 2024 Section: Research letterFor the first time and in a large study we have shown that in patients with active systemic lupus erythematosus (SLE), health-related quality of life was negatively affected by the presence of moderate-to-severe skin lesions compared with patients with active SLE who had no/mild skin lesions.
-
Corrected Proof
Research Article 29 April 2024
Long-term consequences on stigmatization and disease burden during adulthood among patients with childhood or adolescence-onset atopic dermatitis
Bruno Halioua and othersBritish Journal of Dermatology, ljae176, https://doi.org/10.1093/bjd/ljae176Published: 29 April 2024 Section: Research letterThe World Health Organization is calling on governments to take action to reduce the stigmatization of patients with skin diseases, highlighting the significant psychosocial burden experienced by patients with atopic dermatitis (AD) from childhood onwards. This cross-sectional study reveals that stigma experienced in childhood or adolescence increases the risk of disease burden, stress and stigma in adulthood, underlining the importance of reinforced psychological support. It highlights the need for dermatologists to target these patients, in order to improve their quality of life.
-
Corrected Proof
Article Commentary 29 April 2024
Dystrophic epidermolysis bullosa: from disease biology to biologic therapy
Liat SamuelovBritish Journal of Dermatology, ljae182, https://doi.org/10.1093/bjd/ljae182Published: 29 April 2024 Section: Commentary -
Corrected Proof
Research Article 28 April 2024
De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort study
Kimberly Tang and othersBritish Journal of Dermatology, ljae184, https://doi.org/10.1093/bjd/ljae184Published: 28 April 2024 Section: Research letterUsing a population-level cohort analysis, our study demonstrates that, although rare, de novo autoimmune cutaneous connective tissue diseases (AiCTDs) in the setting of immune checkpoint inhibitors (ICIs) are not associated with a greater risk of mortality and overall approach a statistically significant decrease in mortality when compared with patients treated with ICIs who do not experience cutaneous immune-related adverse events. These findings are significant and highly relevant to dermatologists and oncologists caring for ICI recipients as it adds to the limited information on development of cutaneous AiCTD following ICI administration, for which enhanced understanding is critical to improving the care for this challenging patient population.
-
Corrected Proof
Research Article 26 April 2024
High intratumoral 5-hydroxymethylcytosine levels protect against disease relapse in patients with atypical fibroxanthoma and pleomorphic dermal sarcoma
Thilo Gambichler and othersBritish Journal of Dermatology, ljae171, https://doi.org/10.1093/bjd/ljae171Published: 26 April 2024 Section: Research letterHydroxymethylation plays a significant role in cancer development and progression. We hypothesized that hydroxymethylation markers may have prognostic potential in AFX/PDS (atypical fibroxanthoma/pleomorphic dermal sarcoma) as also observed in other tumours. Moreover, we wanted to find out whether hydroxymethylation markers might aid differentiation between AFX and PDS.
-
Corrected Proof
Discussion 26 April 2024
Expanding global health dermatology leadership: launching the GLODERM international mentorship programme
Alexis G Strahan and othersBritish Journal of Dermatology, ljae164, https://doi.org/10.1093/bjd/ljae164Published: 26 April 2024 Section: PerspectivesThe lack of access to dermatological care is a global health crisis. Providing intentional mentorship to emerging leaders in low- and middle-income countries is foundational to increasing access to care. The GLODERM Mentorship Programme is a first-of-its-kind programme created to support changemakers in global health dermatology in enhancement of leadership skills.
-
Corrected Proof
Article Commentary 25 April 2024
The pleiotropic role of interleukin-13 in the pathogenesis of atopic dermatitis
Coco Dekkers and Marjolein de Bruin-WellerBritish Journal of Dermatology, ljae174, https://doi.org/10.1093/bjd/ljae174Published: 25 April 2024 Section: Commentary -
Corrected Proof
Research Article 24 April 2024
Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?
Jesper Bo Nielsen and othersBritish Journal of Dermatology, ljae175, https://doi.org/10.1093/bjd/ljae175Published: 24 April 2024 Section: Original ArticleBiopsy rates increased by a factor of 1.9 while melanoma incidence increased 2.5-fold. The rate of melanoma precursors increased by a factor of 12. Mortality varied slightly from year to year without any significant time trend. A lowered threshold of melanoma diagnosis among pathologists, increased diagnostic activity in the presence of overdiagnosis and the introduction of immunotherapy for melanoma could explain the discrepancy between incidence and mortality.
-
Corrected Proof
Research Article 24 April 2024
Gasdermin E-mediated keratinocyte pyroptosis participates in the pathogenesis of psoriasis by promoting skin inflammation
Yingfei Li and othersBritish Journal of Dermatology, ljae179, https://doi.org/10.1093/bjd/ljae179Published: 24 April 2024 Section: Original Article -
Corrected Proof
Research Article 24 April 2024
Dupilumab in chronic actinic dermatitis: a retrospective case series
Marese O’Reilly and othersBritish Journal of Dermatology, ljae180, https://doi.org/10.1093/bjd/ljae180Published: 24 April 2024 Section: Research letterWe report a retrospective case series from two UK photobiology units of 12 patients with concomitant atopic dermatitis (AD) and chronic actinic dermatitis (CAD) treated with dupilumab as a systemic monotherapy. While dupilumab is an effective therapy for moderate-to-severe AD, our results suggest that it may be less effective for the photosensitivity of CAD. In 11 of 12 patients with CAD, dupilumab was associated with improvement in dermatitis, but only half the patients noted improvement in photosensitivity.
-
Corrected Proof
Research Article 22 April 2024
Programmed death receptor-1 and programmed death ligand-1 checkpoint inhibition-associated bullous pemphigoid: a propensity-matched retrospective cohort study
Katelyn Sarkovics and othersBritish Journal of Dermatology, ljae172, https://doi.org/10.1093/bjd/ljae172Published: 22 April 2024 Section: Research letterWe provide a comparison of the bullous pemphigoid (BP)-free survival probability in patients starting PD-1/PD-L1 inhibitors and DPP-4 inhibitors that has not been previously demonstrated in other studies. A propensity-matched retrospective cohort study performed with TriNetX participants revealed a significantly increased risk of BP in patients starting PD-1/PD-L1 inhibitors, especially in male patients and those aged > 65 years.